Superiority of mosapride citrate to picosulfate sodium as a laxative for withdrawal from regular enemas in children with severe functional constipation

Background: Severe functional constipation (FC) with low bowel movement frequency (BMF) of ?1 day/week and hard stools oftenrequires regularly repeated enemas or often leads to enema dependency (ED). Aim: The current study aimed to compare the efficacy of mosapride citrate (Mo) with the traditional stimulant laxative picosulfate sodium (Pi) for withdrawal from ED in children with severe FC. Results: Twenty-four treatment-naïve patients who met the Rome IV diagnostic criteria for FC seen at our center for 8 years from 2012 were enrolled. Glycerin enema was repeated until the BMF was ?3.5 days/week. Simultaneously, Mo at 0.3 mg/kg/day (n=11) or Pi at 0.25 mg/kg/day (n=13) was administered concomitantly with magnesium oxide or lactulose. The proportion of withdrawal from ED was significantly higher in the Mo group than Pi group during the 4 months observational period (90.9% vs. 46.2%, respectively; p=0.034) and shorter in time to withdraw from ED (0 vs. 3.5 months, respectively; p=0.015). Conclusion: Mo is more effective than Pi for withdrawal from ED in children with severe FC.

Stability Indicating RP-UPLC Method for Simultaneous Estimation of Rabeprazole Sodium and Mosapride Citrate in Tablet Dosage form

RP- UPLC method was developed and validated for the simultaneous determination of Rabeprazole sodium and Mosapride citrate in tablet dosage form. The separation was achieved on a BEH C18 (50mm × 2.1mm× 1.7µm) column using mobile phase of Ammonium acetate buffer: Acetonitrile (60:40% v/v). The flow rate was 0.4 ml/min and detection was carried out at 270nm and column oven 35ºC. Rabeprazole sodium and Mosapride citrate was subjected to stress condition including Acidic, Alkaline, Oxidation, Photolysis and Thermal degradation. This method was validated as per ICH (Q2R1) guideline.